Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial

FRI0155 Long-term cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis – 5 year follow-up data from the best study

(2014) W. van den Hout et al.   ANNALS OF THE RHEUMATIC DISEASES

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

(2013) James R. O'Dell et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Randomized Registry Trial — The Next Disruptive Technology in Clinical Research?

(2013) Michael S. Lauer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis

(2013) Jonas K. Eriksson et al.   JAMA Internal Medicine

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial

(2012) Johan A Karlsson et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

(2012) Larry W. Moreland et al.   ARTHRITIS AND RHEUMATISM

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

(2012) Ronald F van Vollenhoven et al.   LANCET

External review and validation of the Swedish national inpatient register

(2011) Jonas F Ludvigsson et al.   BMC PUBLIC HEALTH

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) M. Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009

(2010) M Neovius et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review

(2010) Gabrielle van der Velde et al.   ARTHRITIS CARE & RESEARCH

The cost-utility analysis of the BeSt trial: Is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al

(2009) Maarten Boers   ARTHRITIS AND RHEUMATISM

Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis

(2009) Wilbert B. Van den Hout et al.   ARTHRITIS AND RHEUMATISM

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

(2009) Takeru Shiroiwa et al.   HEALTH ECONOMICS

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

(2009) RF van Vollenhoven et al.   LANCET